From Nasdaq: 2025-06-11 21:21:00

Klotho Neurosciences (KLTO) saw an 800% stock surge on June 9, 2025, thanks to promising pre-clinical study results showing that elevating Klotho gene expression could potentially reduce age-related degeneration and extend lifespan and healthspan.

The company’s research focuses on the s-KL protein, which has anti-aging potential by affecting cellular injury, stress, and inflammation. Using an AAV9 delivery vector, KLTO increased serum s-KL concentrations and achieved a 20% increase in lifespan in pre-clinical studies.

KLTO holds exclusive patents for using s-KL to treat age-related disorders in the USA, Europe, and China. However, despite the exciting research, the path to a viable product involves extensive human testing, with no guarantee of success given historical pre-clinical treatment failures.

KLTO’s stock performance has been extremely volatile, falling from highs above $12 to below $0.20 before the recent rise to around $2. This volatility reflects the risky nature of investing in early-stage biotech companies like KLTO.

Investing in KLTO carries significant risks due to its early-stage science, lack of revenue, cash burn, and stock volatility. Investors with high risk tolerance may consider diversified options like Trefis’s High Quality Portfolio, which spreads risk across multiple companies and sectors.

For those interested in investing, Trefis offers Market-Beating Portfolios and Price Estimates to help guide investment decisions. Remember, the views expressed here are the author’s and may not reflect those of Nasdaq, Inc.



Read more at Nasdaq: What’s Happening With Klotho Neurosciences Stock?